Streetwise Reports' Article Archives — October 2021 back to current month (17)
Cannabis Firm to Enter Colorado Market Via Acquisition (10/27/2021)
The target company "brings numerous positives to Stem Holdings dba Driven By Stem," noted a Noble Capital markets report.
Medpace Shares Rise 13% on Higher Q3 Earnings & Forward Outlook (10/26/2021)
Shares of Medpace Holdings Inc. climbed to a new 52-week high after the CRO, a provider of full-service clinical trial development services, reported financial results for Q3/21 that included a 28.3% increase in YoY revenue.
Global Distribution Deal for Antibiotic Alternative for Livestock ‘Could Be a Game Changer’ (10/25/2021)
Analyst David Bautz at Zacks Small-Cap Research wrote bullishly on Avivagen's eight-year distribution deal targeting the U.S., Brazil, and Thailand in an Oct. 11 report: The AB Vista deal “could be a game changer for the company as Avivagen now has a global partner that gives immediate credibility to the OxC-beta technology."
Radius Health Reports Positive Topline Data from Ph. 3 Metastatic Breast Cancer Trial (10/20/2021)
Shares of Radius Health Inc. traded 17% higher after the firm reported positive topline results from the Phase 3 EMERALD study of elacestrant in ER+/HER2- advanced or metastatic breast cancer (mBC).
Aquaculture Firm to Provide US Gulf Coast Distributor with 25,000 Pounds of Live Gourmet-Quality Shrimp (10/19/2021)
NaturalShrimp Inc.'s shares traded 12% higher after the company reported it entered into an agreement with Gulf Seafood Inc. for delivery of 25,000 lbs. of naturally grown, chemical and antibiotic-free, live shrimp.
New French Vaccine May 'Play an Important Role in Overcoming' COVID-19 (10/18/2021)
Valneva SE shares traded 40% higher after the company reported positive results from its Phase 3 clinical trial of its COVID-19 vaccine candidate, VLA2001. The firm claimed that VLA2001 produced superior neutralizing antibody titer levels compared to AstraZeneca's AZD1222 (ChAdOx1-S) vaccine in the study.
DarioHealth Contracts With National Health Plan to Offer Behavioral Health Services to Millions of Members (10/14/2021)
DarioHealth Corp. shares traded 17% higher after the company reported it entered into an agreement with an unnamed national healthcare provider to make its behavioral health products available to millions of the plan's members.
Company Releases iOS-Based App for Cannabis Purchase and Delivery (10/14/2021)
The potential is "enormous" for Stem Holdings Inc. dba Driven By Stem's new app, Budee Cannabis Delivery, given it is available in the Apple App Store, a Noble Capital Markets report noted.
Pacira Bids to Acquire Flexion to Expand Leadership Position in Non-Opioid Pain Management (10/11/2021)
Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc. for $8.00 per share in cash plus an additional non-tradeable contingent value right worth up to $8.00 per share in cash if five specific milestones are met.
ChemoCentryx Shares Double After FDA Approves TAVNEOS™ for Treatment of ANCA-Associated Vasculitis (10/10/2021)
Shares of ChemoCentryx Inc. traded 96% higher after the company reported the U.S. FDA approved its orally administered TAVNEOS™ (avacopan) for use in treatment of ANCA-associated vasculitis, a systemic autoimmune disease that often results in kidney or other major organ damage and failure that can be fatal if left untreated.
Shares of Dutch oncology company Merus NV traded higher after the firm presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Reliq's Telemedicine Platform Helps Free Up Hospital Space for COVID-19 Delta Patients (10/06/2021)
Simultaneously, demand is growing for Reliq Health's iUGO Care software as virtual healthcare delivery increases during the COVID-19 pandemic.
Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs (10/06/2021)
Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACERᵀᴹ AAV capsids that will be utilized to enhance Pfizer's neurologic and cardiovascular gene therapy programs. Voyager will receive an upfront payment of $30 million and is eligible to receive up to $600 million more plus product sales-based royalties, if all options are exercised and certain milestones are achieved.
SmileDirectClub Granted Patent for Mobile Oral Care Bus to Serve Remote Regions in the US & UK (10/05/2021)
SmileDirectClub Inc. shares traded 15% higher after the company reported that the U.S. Patent & Trademark Office has allowed its new patent for the firm's mobile SmileBus concept whereby its SmileShop on wheels is mobilized to expand access to convenient, affordable oral care in remote areas across the U.S. and the U.K.
Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial (10/04/2021)
Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints and decreased monthly focal seizure frequency by 50% or greater from baseline.
Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics, oral antiviral molnupiravir reduced risk of hospitalization or death by 50% versus placebo in patients with mild or moderate COVID-19. Merck plans to submit an Emergency Use Authorization application to the U.S. FDA and if authorized it would make molnupiravir the first approved oral antiviral medicine for COVID-19.
Coverage Initiated on Nanomedicine Firm, Upside 'Potentially Significant' With Upcoming Trial Results (10/01/2021)
"With Clene's potential to realize several multibillion-dollar revenue opportunities, we see its roughly $480 million enterprise value as offering attractive risk-reward," an Oppenheimer report noted.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
